Exec Chat: MeMed Improves Diagnostics To Combat Antimicrobial resistance
Executive Summary
Kfir Oved, co-founder and CTO of MeMed, talked to Medtech Insight about diagnostic testing that can differentiate bacterial and viral infections to fight antimicrobial resistance.
You may also be interested in...
Interview: What Does Breakthrough Designation Mean For Manus Neurodynamica?
Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.
MeMed Secures $93M Financing To Commercialize Diagnostics Platform
The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.
Minute Insight: MeMed Announces Viral/Bacterial Infection Differentiation Results, Commercial Partnership
DiaSorin will distribute MeMed BV, a rapid point-of-care test that can differentiate bacterial and viral infections, under a new commercial agreement.